Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(2):238–243. doi: 10.1038/bjc.1997.368

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

L Y Dirix 1, P B Vermeulen 1, A Pawinski 1, A Prové 1, I Benoy 1, C De Pooter 1, M Martin 1, A T Van Oosterom 1
PMCID: PMC2223937  PMID: 9231925

Abstract

The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) was determined in the serum of 90 untreated and 42 treated metastatic cancer patients, including patients with colorectal, breast, ovarian and renal carcinomas, with an enzyme-linked immunosorbent assay (ELISA). Levels higher than the 95th percentile of the concentrations of a control group, i.e. 7.5 pg ml(-1) for bFGF and 500 pg ml(-1) for VEGF, were identified as 'elevated'. One measurement during follow-up was included into the analysis per patient. For 19 treated patients, consecutive serum samples were analysed. Fifty-seven per cent of all untreated patients had elevated serum levels of one or both angiogenic factors. The fraction of patients with elevated serum levels of bFGF and/or VEGF was similar in the different tumour types. Agreement of bFGF levels and VEGF levels, classified in relation to their respective cut-off values, was present in 67% of all patients. Fifty-eight per cent of the patients with progressive disease during treatment compared with 15% of the patients showing response to treatment (chi-squared test P < 0.05) had elevated bFGF and/or VEGF serum levels. When consecutive serum samples were analysed, two-thirds of the patients showing progressive disease had increasing serum levels of the angiogenic factors compared with less than one-tenth of the patients showing response (chi-squared test P < 0.05). The lack of association between the serum bFGF and VEGF levels and the tumour type may suggest an aspecific host reaction responsible for solid tumour-related angiogenesis. The main determinants of the serum bFGF and VEGF concentration are the progression kinetics of the metastatic carcinomas.

Full text

PDF
238

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger D. P., Herbstritt L., Dengler W. A., Marmé D., Mertelsmann R., Fiebig H. H. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol. 1995 Oct;6(8):817–825. doi: 10.1093/oxfordjournals.annonc.a059322. [DOI] [PubMed] [Google Scholar]
  2. Chodak G. W., Hospelhorn V., Judge S. M., Mayforth R., Koeppen H., Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res. 1988 Apr 15;48(8):2083–2088. [PubMed] [Google Scholar]
  3. Chodak G. W., Scheiner C. J., Zetter B. R. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med. 1981 Oct 8;305(15):869–874. doi: 10.1056/NEJM198110083051506. [DOI] [PubMed] [Google Scholar]
  4. Dirix L. Y., Vermeulen P. B., Hubens G., Benoy I., Martin M., De Pooter C., Van Oosterom A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996 Oct;7(8):843–848. doi: 10.1093/oxfordjournals.annonc.a010764. [DOI] [PubMed] [Google Scholar]
  5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  6. Fox S. B., Gatter K. C., Bicknell R., Going J. J., Stanton P., Cooke T. G., Harris A. L. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res. 1993 Sep 15;53(18):4161–4163. [PubMed] [Google Scholar]
  7. Gasparini G., Harris A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995 Mar;13(3):765–782. doi: 10.1200/JCO.1995.13.3.765. [DOI] [PubMed] [Google Scholar]
  8. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993 Nov;69(5):508–517. [PubMed] [Google Scholar]
  9. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989 Dec 8;246(4935):1309–1312. doi: 10.1126/science.2479987. [DOI] [PubMed] [Google Scholar]
  10. Kondo S., Asano M., Matsuo K., Ohmori I., Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta. 1994 Mar 31;1221(2):211–214. doi: 10.1016/0167-4889(94)90016-7. [DOI] [PubMed] [Google Scholar]
  11. Kuwabara K., Ogawa S., Matsumoto M., Koga S., Clauss M., Pinsky D. J., Lyn P., Leavy J., Witte L., Joseph-Silverstein J. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4606–4610. doi: 10.1073/pnas.92.10.4606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Leek R. D., Harris A. L., Lewis C. E. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol. 1994 Oct;56(4):423–435. doi: 10.1002/jlb.56.4.423. [DOI] [PubMed] [Google Scholar]
  13. Li V. W., Folkerth R. D., Watanabe H., Yu C., Rupnick M., Barnes P., Scott R. M., Black P. M., Sallan S. E., Folkman J. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet. 1994 Jul 9;344(8915):82–86. doi: 10.1016/s0140-6736(94)91280-7. [DOI] [PubMed] [Google Scholar]
  14. Liu Y., Cox S. R., Morita T., Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res. 1995 Sep;77(3):638–643. doi: 10.1161/01.res.77.3.638. [DOI] [PubMed] [Google Scholar]
  15. Mattern J., Koomägi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996 Apr;73(7):931–934. doi: 10.1038/bjc.1996.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McCarty L. P., 3rd, Karr S. M., Harris B. Z., Michelson S. G., Leith J. T. Comparison of basic fibroblast growth factor levels in clone A human colon cancer cells in vitro with levels in xenografted tumours. Br J Cancer. 1995 Jul;72(1):10–16. doi: 10.1038/bjc.1995.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schultz-Hector S., Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 1993 Mar 15;53(6):1444–1449. [PubMed] [Google Scholar]
  18. Schweigerer L., Neufeld G., Friedman J., Abraham J. A., Fiddes J. C., Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature. 1987 Jan 15;325(6101):257–259. doi: 10.1038/325257a0. [DOI] [PubMed] [Google Scholar]
  19. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 Oct 29;359(6398):843–845. doi: 10.1038/359843a0. [DOI] [PubMed] [Google Scholar]
  20. Sliutz G., Tempfer C., Obermair A., Dadak C., Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995 Nov-Dec;15(6B):2675–2677. [PubMed] [Google Scholar]
  21. Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995 Sep 15;55(18):3964–3968. [PubMed] [Google Scholar]
  22. Taniguchi T., Toi M., Inada K., Imazawa T., Yamamoto Y., Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res. 1995 Sep;1(9):1031–1034. [PubMed] [Google Scholar]
  23. Toi M., Kondo S., Suzuki H., Yamamoto Y., Inada K., Imazawa T., Taniguchi T., Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996 Mar 15;77(6):1101–1106. doi: 10.1002/(sici)1097-0142(19960315)77:6<1101::aid-cncr15>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  24. Vermeulen P. B., Verhoeven D., Hubens G., Van Marck E., Goovaerts G., Huyghe M., De Bruijn E. A., Van Oosterom A. T., Dirix L. Y. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol. 1995 Jan;6(1):59–64. doi: 10.1093/oxfordjournals.annonc.a059043. [DOI] [PubMed] [Google Scholar]
  25. Watanabe H., Hori A., Seno M., Kozai Y., Igarashi K., Ichimori Y., Kondo K. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun. 1991 Feb 28;175(1):229–235. doi: 10.1016/s0006-291x(05)81224-0. [DOI] [PubMed] [Google Scholar]
  26. Weidner N., Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol. 1996:167–190. [PubMed] [Google Scholar]
  27. Yamamoto Y., Toi M., Kondo S., Matsumoto T., Suzuki H., Kitamura M., Tsuruta K., Taniguchi T., Okamoto A., Mori T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996 May;2(5):821–826. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES